Study of HL-085 in NRAS Mutant Advanced Melanoma

Study of HL-085 in NRAS Mutant Advanced Melanoma

Publication date: Jun 04, 2019

This is a phase I/II, open-label, dose escalation study to evaluate tolerability, safety, pharmacokinetics and efficacy in patients with NRAS mutant advanced melanoma .

Concepts Keywords
AJCC Chemotherapy
Biopsy Radiation
Bleeding Pharmacokinetics
Central Nervous System Chemotherapy
Chemotherapy Pneumonitis
Congenital MEK inhibitor
Cytologically Antineoplastic drugs
ECG Cancer
Epithelial RTT
Histologically Melanoma
Hypersensitivity Health
Immunotherapy Clinical medicine
Infection Medicine
Infectious Diseases Radiotherapy
Informed Consent Chemotherapy
Interstitial Pneumonitis Radiation
Lesion Surgery
Lung Immunotherapy
Melanoma Tumor
Mutant
Mutation
NCI
Occlusion
Pharmacokinetics
Pigment
Radiotherapy
Shanghai
Syndrome
Tolerability
Trauma
Tumor

Semantics

Type Source Name
disease MESH pneumonitis
disease DOID Interstitial lung disease
disease MESH Interstitial lung disease
disease MESH infection
disease MESH Retinal pigment epithelial detachment
disease DOID Retinal Vein Occlusion
disease MESH Retinal Vein Occlusion
disease MESH Retinal diseases
disease MESH infectious diseases
disease MESH bleeding
disease MESH ECG
disease DOID hypersensitivity
disease MESH hypersensitivity
gene UNIPROT NRAS
disease MESH Melanoma
disease DOID Melanoma
pathway BSID Melanoma
disease MESH tumor
gene UNIPROT MAP2K7
drug DRUGBANK Chorionic Gonadotropin (Human)
gene UNIPROT CGA

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *